Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 2 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Immunogen Inc. currently manages 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. This workload is distributed across 2 distinct examiners and 2 distinct art units, indicating a diversified prosecution front even with a small volume of active matters. The presence of various units suggests the portfolio may cover varied technical aspects within the field. Practitioners should note that the examiners are operating in separate environments, which may lead to different procedural expectations for each case.
BURKETT, DANIEL JOHN is identified as the busiest examiner for this portfolio, currently handling 1 pending office action. This represents a portion of the total volume for the company. Practitioners should monitor the 2 distinct examiners to ensure consistent arguments across the 2 distinct art units involved. The distribution of the current matters shows a balanced workload across the patent office. By analyzing the specific tendencies of BURKETT, DANIEL JOHN, the company can better predict the timeline for the matter under review. This focused oversight is essential when dealing with various individuals in the Biotechnology & Pharmaceuticals sector.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (33%) |
| Multi-statute (no §101) | 1 (33%) |
| No statute on record | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| JOHNSON, TIRONE DEREK | 1 | 0.0% | +0.0% |
| BURKETT, DANIEL JOHN | 1 | 62.6% | +33.2% |
| KIM, YUNSOO | 1 | 65.9% | +34.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18634736 | ANTI-FOLR1 IMMUNOCONJUGATE REGIMENS | JOHNSON, TIRONE DEREK | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18054076 | METHODS OF TREATMENT USING ANTI-CD123 IMMUNOCONJUGATES | KIM, YUNSOO | 22d |
| 18683361 | IMPROVED METHODS FOR PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES | BURKETT, DANIEL JOHN | — |
| Art Unit | Apps |
|---|---|
| 1624 | 1 |
| 1641 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18634736 | ANTI-FOLR1 IMMUNOCONJUGATE REGIMENS | JOHNSON, TIRONE DEREK | — | §102§103§112 | Non-Final OA | — | Pending | Apr 12, 2024 |
| 18683361 | IMPROVED METHODS FOR PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES | BURKETT, DANIEL JOHN | 1624 | §102DP | Non-Final OA | — | Pending | Feb 13, 2024 |
| 18054076 | METHODS OF TREATMENT USING ANTI-CD123 IMMUNOCONJUGATES | KIM, YUNSOO | 1641 | Other | Final Rejection | 22d | Pending | Nov 09, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial